The MC4R (Melanocortin 4 Receptor) gene encodes a G protein-coupled receptor (GPCR) that plays a critical role in energy homeostasis, appetite regulation, and metabolic function. As one of five melanocortin receptors (MC1R-MC5R), MC4R is expressed primarily in the central nervous system and regulates food intake, energy expenditure, and body weight. Located on chromosome 18q21.3, MC4R is one of the most common monogenic causes of obesity in humans.
| Property |
Value |
| Gene Symbol |
MC4R |
| Full Name |
Melanocortin 4 Receptor |
| Chromosomal Location |
18q21.3 |
| NCBI Gene ID |
4162 |
| OMIM ID |
601665 |
| Ensembl ID |
ENSG00000137273 |
| UniProt ID |
P32246 |
| Encoded Protein |
Melanocortin 4 receptor |
| Protein Length |
332 amino acids |
| Molecular Weight |
~37 kDa |
¶ Gene Structure and Organization
The MC4R gene consists of a single exon, typical of the melanocortin receptor family. This single-exon structure simplifies transcription and avoids alternative splicing complications. The gene encodes a classic seven-transmembrane GPCR with characteristic features:
- N-terminal extracellular domain: Contains glycosylation sites
- Seven transmembrane helices: Classic GPCR architecture
- Three extracellular loops: Ligand binding interface
- Three intracellular loops: G protein coupling
- C-terminal intracellular tail: Phosphorylation sites and desensitization motifs
The MC4R promoter contains elements for tissue-specific expression:
- Neuronal enhancers: Drive expression in specific brain regions
- Hormone response elements: Allow modulation by metabolic signals
- Circadian elements: Link to daily feeding rhythms
¶ Protein Structure and Function
MC4R belongs to the melanocortin receptor subfamily, which includes:
| Receptor |
Primary Ligands |
Main Function |
| MC1R |
α-MSH, ACTH |
Pigmentation, inflammation |
| MC2R |
ACTH |
Steroidogenesis |
| MC3R |
α-MSH, γ-MSH |
Energy homeostasis |
| MC4R |
α-MSH, β-MSH |
Appetite, energy expenditure |
| MC5R |
α-MSH |
Exocrine function |
¶ Ligand Binding
MC4R binds several melanocortin peptides:
- α-MSH (α-Melanocyte Stimulating Hormone): Primary agonist
- β-MSH: Agonist with lower potency
- γ-MSH: Agonist at certain splice variants
- ACTH (Adrenocorticotropic Hormone): Agonist
Agouti-related Protein (AGRP): The endogenous inverse agonist/antagonist provides tonic inhibition of MC4R signaling, establishing a baseline that can be modulated by α-MSH.
MC4R activates multiple signaling pathways:
Primary (Gs-mediated) Pathway:
- Agonist binding induces conformational change
- Gs protein activation
- Adenylyl cyclase stimulation
- Increased cAMP
- Protein kinase A (PKA) activation
- Phosphorylation of downstream targets
- Gene transcription effects
Alternative Pathways:
- Gi/o coupling: Inhibition of cAMP in some contexts
- ERK/MAPK activation: Through β-arrestin
- Calcium signaling: Through IP3 pathways
MC4R undergoes multiple regulatory processes:
- Phosphorylation: By GRKs, promoting β-arrestin binding
- Internalization: Via clathrin-mediated endocytosis
- Desensitization: Homologous and heterologous
- Recycling: Return to membrane or degradation
MC4R shows distinctive patterns in the brain:
Hypothalamic Expression:
- Paraventricular nucleus (PVN): Highest expression; projects to autonomic centers
- Arcuate nucleus (ARC): On POMC and NPY neurons; integration of metabolic signals
- Lateral hypothalamus: Feeding behavior control
- Dorsomedial hypothalamus: Energy expenditure regulation
Extra-hypothalamic Expression:
- Spinal cord: Pain modulation
- Dorsal raphe nucleus: Mood and emotional regulation
- Hippocampus: Learning and memory
- Cortex: Cognitive functions
Lower levels of MC4R expression are found in:
- Adrenal gland: Modulation of steroidogenesis
- Peripheral nerves: Pain transduction
- Immune cells: Anti-inflammatory effects
- Gastrointestinal tract: Gut-brain signaling
MC4R is a central integrator of energy balance signals:
Anorexigenic ( appetite-suppressing) Signaling:
- α-MSH binding activates MC4R
- Reduces food intake
- Increases energy expenditure
- Promotes weight loss
Orexigenic (appetite-promoting) Tone:
- AGRP acts as inverse agonist
- Blocks α-MSH action
- Increases food intake
- Promotes weight gain
¶ POMC and NPY Integration
The arcuate nucleus houses key MC4R-expressing neurons:
- POMC (Pro-opiomelanocortin) neurons: Produce α-MSH, project to MC4R neurons
- NPY/AgRP neurons: Produce AGRP, antagonize MC4R
This creates a balanced system where:
- POMC activation → MC4R activation → reduced feeding
- NPY/AGRP activation → MC4R inhibition → increased feeding
Beyond food intake, MC4R regulates:
- Thermogenesis: Brown adipose tissue activation
- Physical activity: Motor behavior and exploration
- Basal metabolic rate: Through autonomic regulation
MC4R mutations are the most common monogenic cause of obesity:
- Prevalence: ~5-6% of severe early-onset obesity
- Inheritance: Autosomal dominant with incomplete penetrance
- Mechanism: Loss-of-function mutations reduce signaling
- Phenotype: Hyperphagia, early-onset obesity, increased linear growth
Common Mutations:
- Frameshift mutations
- Missense mutations (particularly in transmembrane domains)
- Deletion mutations
Genotype-Phenotype:
- Complete loss-of-function: Severe phenotype
- Partial function: Variable severity
- Heterozygotes: Often manifest obesity
MC4R dysfunction contributes to metabolic syndrome:
- Insulin resistance
- Glucose intolerance
- Dyslipidemia
- Increased cardiovascular risk
The melanocortin system has been implicated in AD pathogenesis:
Neuroinflammation:
- MC4R signaling has anti-inflammatory effects
- Reduced signaling may contribute to neuroinflammation
- Therapeutic potential for MC4R agonists
Metabolic Dysfunction:
- AD patients often have metabolic syndrome
- MC4R variants may modify AD risk
- Energy homeostasis dysregulation in AD
Cognitive Function:
- MC4R in hippocampus may affect memory
- Signaling modulates synaptic plasticity
- Potential for cognitive enhancement
Emerging evidence links MC4R to PD:
Nigrostriatal System:
- MC4R expressed in substantia nigra
- May modulate dopaminergic function
- Potential role in PD pathogenesis
Metabolic Aspects:
- PD patients often have weight loss
- MC4R dysfunction may contribute
- Energy expenditure alterations
Therapeutic Potential:
- MC4R agonists may have neuroprotective effects
- Anti-inflammatory actions relevant to PD
- Clinical trials ongoing
Huntington's Disease:
- Metabolic dysfunction is common
- MC4R variants may modify progression
Multiple Sclerosis:
- MC4R signaling has immunomodulatory effects
- Potential therapeutic target
Over 200 MC4R mutations have been identified:
- Missense mutations (~60%): Protein misfolding or trafficking issues
- Frameshift mutations: Truncated proteins
- Nonsense mutations: Premature stop codons
- Deletions: Loss of functional protein
- Splice variants: Alternative splicing effects
Class I (Trafficking defects):
- Mutations in extracellular/transmembrane domains
- Protein retained in ER
- Can sometimes be rescued by pharmacological chaperones
Class II (Ligand binding defects):
- Mutations in ligand-binding pocket
- Reduced agonist affinity
Class III (Signaling defects):
- Mutations in intracellular domains
- Impaired G protein coupling
- Variant frequency: ~2-3% of population carry rare variants
- Founder mutations: Some populations have specific variants
- Loss-of-function carriers: Higher BMI, increased obesity risk
Several MC4R agonists have been developed:
Setmelanotide (Imcivree):
- FDA approved for rare genetic obesity (POMC, LEPR deficiency)
- Highly selective MC4R agonist
- Marked weight loss in clinical trials
- Also being studied for Bardet-Biedl syndrome
Other Agonists:
- Peptide agonists in development
- Small molecule agonists
- Brain-penetrant vs. peripheral-selective options
AGRP-based approaches:
- Block excessive MC4R activation
- May have different side effect profiles
- MC4R agonists + other anti-obesity agents
- GIP/GLP-1 receptor co-agonists with MC4R activity
- Lifestyle intervention with pharmacotherapy
Efficacy:
- Weight loss of 5-10% in trials
- Improvements in metabolic parameters
- Long-term maintenance challenging
Side Effects:
- Most common: skin darkening (melanin), nausea
- Potential for increased blood pressure
- Psychiatric effects (mood changes)
Mc4r Knockout Mice:
- Develop obesity with hyperphagia
- Reduced energy expenditure
- Insulin resistance
- Useful for therapeutic testing
Humanized Mice:
- Express human MC4R
- Rescue knockout phenotype
- Allow testing of human variants
Transgenic Models:
- Conditional knockouts
- Cell-type specific deletion
- Reporter lines
- Heterologous expression: HEK293, CHO cells
- Neuronal cell lines: For CNS signaling
- iPSC-derived neurons: Patient-specific models
¶ Interactions and Pathways
MC4R interacts with:
- G proteins: Gs, Gi/o
- β-arrestins: For internalization
- GRKs: For phosphorylation
- Chaperones: For folding (e.g., RABEP1)
MC4R participates in:
- POMC-MC4R circuit: Primary feeding regulation
- NPY-MC4R circuit: Integration of orexigenic signals
- Autonomic circuits: Energy expenditure control
- cAMP/PKA pathway: Primary signaling
- MAPK/ERK pathway: Non-canonical
- PI3K/Akt pathway: Metabolic effects
| Aspect |
Details |
| Primary disease |
Monogenic obesity (MC4R deficiency) |
| Inheritance |
Autosomal dominant |
| Key feature |
Hyperphagia, early-onset obesity |
| Treatment |
Setmelanotide (for POMC/LEPR), supportive |
| Neurodegeneration |
Implicated in AD, PD |